Objective:

To evaluate the clinical effectiveness and safety of efgartigimod in patients with Guillain–Barré syndrome (GBS).

Approach:

Key Findings:

• 52 patients were enrolled: IVIg (n=20), efgartigimod (n=16), ISE (n=16).
• Good improvement was higher in the efgartigimod group than the IVIg group at week 2 (37.5% vs. 0%, p<0.01) and final visit (81.3% vs. 40.0%, p=0.02).
• The proportion with GBS-DS ≤1 was consistently higher in the efgartigimod group.
• The mean time to reach GBS-DS ≤1 was shorter in the efgartigimod group (2.6 weeks) compared to IVIg (3.1 weeks) and ISE (2.8 weeks).
• The incidence of treatment-related adverse events was lower in the efgartigimod group (18.8%) compared to IVIg (50.0%) and ISE (43.8%).

Interpretation:

No new safety concerns were identified in the study.

Limitations:

• The study's retrospective design limits the ability to establish comparative efficacy.
• Small sample size may affect the generalizability of the findings.
• Lack of randomization and control groups.

Conclusion:

Larger, well-controlled trials are necessary to further evaluate the efficacy and safety of efgartigimod in GBS.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.